The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
How can you invest in a company if you don’t even understand the technology or the testing of that technology?
“ As of writing this, Seeing Machines claims its driver monitoring systems have collectively travelled over 13 billion kilometres, amassing tons of real-world driving data.”
From an article published 15th August, 2023!
Short,
The only view that matters is that DMS is mandated into every new car in Europe in coming years which will be followed by the US and the rest of the world. OEM’s have also realised that they can utilise the cameras used in dms to monetise and modernise the incabin environment by understanding where the driver is looking which is driving features never thought possible previously.
Which company is the ultimate winner is still up for debate but SEE have positioned themselves well to take a significant share of the market.
Seriously go and do some more research on the technology and where it’s used in hands free. Didn’t realise a 18 wheeler would be coming straight at you on a motorway! The situations you are talking about draw on the ADAS technology not dms!
13 billion kilometres of DMS monitored drivers have gone into the AI models driving the tech.
Why?
This is the agenda..
“ The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. The Committee will discuss new drug application (NDA) 215500, for eflornithine tablets, submitted by USWM, LLC (doing business as US WorldMeds). The proposed indication (use) for this product is to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma who have completed multiagent, multimodality therapy.”
……. or you could try and research what is happening in the ****pit of all cars and understand what tracking of the eyes means for the many features which will be coming to all vehicles……it’s not just about safety, but that is the most important aspect of the technology.
From the original collaboration with Vollins that lead to the licence.
“ The Agreement positions Seeing Machines to work closely with Collins to jointly market co-developed solutions across the Aviation industry to deliver its eye-tracking technology solutions to Commercial Air Transport, Business, Military, Rotary Wing, General Aviation and Flight Training customers to address improved safety and efficiencies for both pilot training and flight operations.”
“ Seatbelts and airbags ain't sexy either but they are in all vehicles”
…… and no one knows who makes them. Expectations that PR by SEE will make the general population understand who is behind DMS in their car is fantasy. No one will care, just like nobody knows who makes airbags, seatbelts, ABS, collision warning etc etc etc.
The important companies and people in the automotive industry know and that will eventually result in SEE being highly profitable and integral to incabin monitoring and road safety.
All guesswork. What’s the point?
3996 might get licenced to a large pharma.
6000 might get breakthrough therapy.
Who knows. Your speculation is as pointless as mine above.
All that matters at present is the phase 1 data continues to produce positive data for dose escalation and then expansion.
It is quite clear if that happens then there will be a positive future for the company.
Because SEE market cap is 5 times Cipia’s. What is material to Cipia isn’t material to SEE. Yes SEE have had some significant commercial deals that have not been rewarded/recognised by the market but there are macro reasons for that, and so that is where the market disconnect makes for opportunity.
Eternity?.The company was valued at above £300m+ in March 23 with an SP above 7p…… 3 months ago.
If you think investing in unprofitable growth stocks on AIM are going to get you a quick win in the current high interest rate environment you will be in for a bit of a surprise IMO. At least 12 months from here to sort high rates/inflation out but as interest rates easy SEE will be becoming profitable with massive high margin cash flows due 2025/2026/2027.
Easy hold and ignore for me.
surprise, surprise the fantasy investor thorngoson won’t be at the agm to ask these troubling questions.
as: several patients from multiple cohorts still on treatment as disease has not progressed.
thorn: alistair do you think this lack of disease progression in these patients may be due to a placebo effect?
as: **** off you numpty.